Sobi Buys Rare-Disease Drug Emapalumab, Zooms in on Hematology and Immunology Sobi Buys Rare-Disease Drug Emapalumab, Zooms in on Hematology and Immunology
Rare diseases specialist Swedish Orphan Biovitrum (Sobi) has agreed to buy the drug emapalumab and is reorganizing to increase focus on late-stage development in hematology and immunology.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Family Medicine/Primary Care News Source Type: news
More News: Allergy | Allergy & Immunology | Hematology | Primary Care | Rare Diseases | Sweden Health